Shaji Kumar, MD, presents the case of a 63-year-old woman with R/R multiple myeloma and discusses how recent data updates of bispecifics influence treatment decision-making for patients.
EP. 1: Case Presentation: A 63-Year-Old Woman with Relapsed-Refractory (R/R) Multiple Myeloma
Shaji Kumar, MD, presents a case of a 63-year-old woman with R/R multiple myeloma, shares his initial impression, and assess how clinical relapse impacts treatment decisions in patients with R/R multiple myeloma.
EP. 2: MajesTEC-1 and Teclistamab in Patients with Relapsed-Refractory (R/R) Multiple Myeloma
Dr Shaji Kumar reviews key efficacy and safety outcomes of the updated data from MajesTEC-1, evaluating teclistamab in patients with R/R multiple myeloma.
EP. 3: Bispecifics Under Development for The Treatment of R/R Multiple Myeloma
Dr Shaji Kumar highlights bispecifics under development and how BCMA-targeting therapies impact patient selection for the treatment of R/R multiple myeloma.
EP. 4: Monitoring and Management of Adverse Events Associated with Bispecifics in MM
Dr Kumar shares his perspective on the impact of management and monitoring strategies used to minimize the risk of adverse events in patients treated with teclistamab and other bispecifics.
EP. 5: Advice to Community Oncologists Treating with Bispecifics and Unmet Needs in MM
Dr Shaji Kumar outlines advice for community oncologists and discusses unmet needs for treating patients with R/R multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512